Mews, 2021 - Google Patents
Directing T Cells with Chemically Self-Assembled Nanorings as an Immunotherapy for Targeting Hematological Malignancies and Solid TumorsMews, 2021
- Document ID
- 4341949752188164957
- Author
- Mews E
- Publication year
External Links
Snippet
Engineering cell-to-cell interactions has proven to be quite valuable due to the vast number of therapeutic applications that benefit from this technology. Although genetically engineering artificial receptors onto a patient's cells has shown some success, preparation …
- 206010028980 Neoplasm 0 title abstract description 19
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113286879B (en) | Diversified antigen binding domains, novel platforms and other enhancers for cell therapy | |
| ES3003809T3 (en) | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides | |
| Schneider et al. | A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines | |
| JP7573441B2 (en) | Guidance and navigation control proteins and methods for producing and using same - Patents.com | |
| US20200085869A1 (en) | Therapeutic regimens for chimeric antigen receptor therapies | |
| JP6994456B2 (en) | Anti-mesotelin fully human antibodies and immune effector cells targeting mesothelin | |
| US20210213063A1 (en) | Combination therapy with chimeric antigen receptor (car) therapies | |
| KR102387243B1 (en) | Transgene genetic tags and methods of use | |
| JP2021177768A (en) | New PD-1 immunomodulator | |
| JP2019196383A (en) | Targeted therapy for small cell lung cancer | |
| CN110352068A (en) | The immunity receptor and its application method of synthesis | |
| JP2020533958A (en) | Compositions and Methods for Treating Cancer with Anti-CD19 / CD20 Immunotherapy | |
| Chen et al. | Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer | |
| CN109906231A (en) | Aptamers Chimeric antigen receptor expression cell for The multiple antigen of targeting | |
| TW202237658A (en) | Anti-tnfr2 humanized antibody and use thereof | |
| Zhang et al. | Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on-and off-rates against non-Hodgkin lymphoma: a first-in-human study | |
| Fierle et al. | Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1 | |
| Mews et al. | Multivalent, bispecific αB7-H3-αCD3 chemically self-assembled nanorings direct potent T cell responses against medulloblastoma | |
| KR20230008144A (en) | Chimeric Antigen Receptors Targeting CD19 and Uses Thereof | |
| WO2023200873A2 (en) | Chimeric antigen receptor compositions and methods of using the same | |
| CN112679618A (en) | TRBC 1-targeted humanized chimeric antigen receptor, T cell and application | |
| Mews | Directing T Cells with Chemically Self-Assembled Nanorings as an Immunotherapy for Targeting Hematological Malignancies and Solid Tumors | |
| US20240216517A1 (en) | Pharmaceutical composition for prevention or treatment of lung cancer | |
| WO2024012495A1 (en) | Cell expressing chimeric antigen receptor (car) targeting cd5 and use thereof | |
| US20250043015A1 (en) | Anti-tnfr2 single domain antibody, and preparation method therefor and application thereof |